<?xml version="1.0" encoding="UTF-8"?>
<p id="p0060">Remdesivir is an adenosine analogue developed to treat Ebola. Its effects derive from inhibition of viral replication and RNA synthesis.
 <xref rid="bib8" ref-type="bibr">
  <sup>8</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib9" ref-type="bibr">
  <sup>9</sup>
 </xref> Data supporting treatment of SARS-CoV-2 infection with remdesivir include established potency against coronaviruses in vitro
 <xref rid="bib8" ref-type="bibr">
  <sup>8</sup>
 </xref> and in mouse
 <xref rid="bib10" ref-type="bibr">
  <sup>10</sup>
 </xref> and primate
 <xref rid="bib11" ref-type="bibr">
  <sup>11</sup>
 </xref> models. In vitro studies with SARS-CoV-2 measured a half-maximal effective concentration (EC
 <sub>50</sub>) of 0.77 μM and inhibition of infection in Huh-7 cells.
 <xref rid="bib12" ref-type="bibr">
  <sup>12</sup>
 </xref> Combination with emetine may enhance viral inhibition.
 <xref rid="bib13" ref-type="bibr">
  <sup>13</sup>
 </xref>
</p>
